Category
Current Projects, Protein Therapy, Quality of Life Change
About This Project

Development of NvA-011 for topical application in Dystrophic Epidermolysis Bullosa

Investment summary

Nova Anchora’s lead product in development, NvA-011, a recombinant version of “genetically correct” collagen VII, is designed to be applied topically as a gel and replace collagen VII in the skin of individuals with dystrophic epidermolysis bullosa (DEB).

This investment, alongside other investors, will support IND-enabling activities, such as completion of toxicology studies and finalising manufacturing processes in readiness for clinical trials.